IceCure Medical (NASDAQ:ICCM) Rating Lowered to "Sell" at Wall Street Zen

IceCure Medical (NASDAQ:ICCM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a report on Thursday, May 29th.

IceCure Medical Trading Down 0.5%

NASDAQ:ICCM traded down $0.01 during mid-day trading on Friday, reaching $1.04. 287,317 shares of the company's stock traded hands, compared to its average volume of 485,380. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The firm has a market capitalization of $60.75 million, a price-to-earnings ratio of -3.70 and a beta of 0.31. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.89 and a quick ratio of 1.48. The company has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.17.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the previous year, the business earned ($0.08) EPS. On average, sell-side analysts predict that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Trading of IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC boosted its holdings in IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 58.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,453 shares of the company's stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.